A

Aravive Inc
F:VE11

Watchlist Manager
Aravive Inc
F:VE11
Watchlist
Price: 0.0325 EUR
Market Cap: 2.4m EUR

Operating Margin

-986.3%
Current
Declining
by 146.5%
vs 3-y average of -839.8%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-986.3%
=
Operating Income
$-59.3m
/
Revenue
$7m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-986.3%
=
Operating Income
€-59.3m
/
Revenue
$7m

Peer Comparison

Country Company Market Cap Operating
Margin
US
Aravive Inc
F:VE11
2.4m EUR
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
378.8B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
177.8B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
155.1B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
112.1B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.2B USD
Loading...
AU
CSL Ltd
ASX:CSL
85.7B AUD
Loading...
NL
argenx SE
XBRU:ARGX
41.2B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.3B USD
Loading...
No Stocks Found

Market Distribution

Lower than 93% of companies in the United States of America
Percentile
7th
Based on 14 112 companies
7th percentile
-986.3%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

Aravive Inc
Glance View

Market Cap
2.4m EUR
Industry
Biotechnology

Aravive, Inc. operates as a clinical stage biotechnology company. The company is headquartered in Houston, Texas and currently employs 23 full-time employees. The company went IPO on 2014-03-20. The firm is focused on developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. Its lead product candidate, AVB-500, is an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway associated with tumor cell growth, tumor metastasis, resistance to treatment, and decreased survival. The firm is evaluating AVB-500 in a registrational Phase III trial in platinum resistant ovarian cancer, a Phase Ib/2 trial in second line plus, clear cell renal cell carcinoma (ccRCC), and a Phase Ib/2 trial in first-line treatment of pancreatic adenocarcinoma. The Company’s lead candidate, Aravive-S6 (AVB-S6)-500, is a GAS6 binding protein and AXL decoy receptor. The company is a Fc-fusion protein designed to block the activation of the growth arrest-specific 6 (GAS6)-AXL signaling pathway by intercepting the binding of GAS6 to its receptor AXL.

VE11 Intrinsic Value
Not Available
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-986.3%
=
Operating Income
$-59.3m
/
Revenue
$7m
What is Aravive Inc's current Operating Margin?

The current Operating Margin for Aravive Inc is -986.3%, which is below its 3-year median of -839.8%.

How has Operating Margin changed over time?

Over the last 3 years, Aravive Inc’s Operating Margin has decreased from -536.8% to -986.3%. During this period, it reached a low of -1 023.8% on Jun 30, 2022 and a high of -296% on Sep 30, 2021.

Back to Top